Fortress Biotech - FBIO Stock Forecast, Price & News

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Fortress Biotech Price Performance

NASDAQ:FBIO traded down $0.02 during trading hours on Friday, reaching $1.27. 341,390 shares of the stock traded hands, compared to its average volume of 585,486. The company has a market cap of $136.41 million, a price-to-earnings ratio of -1.50 and a beta of 2.10. The stock has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $1.21. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.31 and a quick ratio of 3.15. Fortress Biotech has a 1 year low of $0.77 and a 1 year high of $3.81.

Fortress Biotech (NASDAQ:FBIO - Get Rating) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.10. The firm had revenue of $23.93 million for the quarter, compared to the consensus estimate of $20.06 million. Fortress Biotech had a negative return on equity of 32.56% and a negative net margin of 88.31%. During the same quarter in the previous year, the business earned ($0.11) earnings per share. On average, analysts predict that Fortress Biotech will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on FBIO. StockNews.com upgraded Fortress Biotech from a "sell" rating to a "hold" rating in a research report on Thursday, May 19th. Cantor Fitzgerald reiterated a "buy" rating and issued a $6.00 price objective on shares of Fortress Biotech in a research report on Friday, May 13th. LADENBURG THALM/SH SH began coverage on Fortress Biotech in a research report on Thursday, August 4th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, B. Riley lowered their price objective on Fortress Biotech from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $9.60.